# A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term Therapy

> **NCT01125748** · PHASE4 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 176 (actual)

## Conditions studied

- Allergic Asthma

## Interventions

- **DRUG:** Omalizumab
- **DRUG:** Placebo
- **DRUG:** Asthma therapies

## Key facts

- **NCT ID:** NCT01125748
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2013-08
- **Final completion:** 2013-08
- **Target enrollment:** 176 (ACTUAL)
- **Last updated:** 2014-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01125748

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01125748, "A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term Therapy". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01125748. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*